Prostate Cancer Metastasis to the Pituitary Gland Manifesting as Corticosteroid Withdrawal, and the Impact of the Switch from Prednisone to Dexamethasone on Survival Time

Current Oncology - Tập 28 Số 6 - Trang 4291-4297
Okeroghene Ataikiru1, Mahmoud Abdelsalam2, Mrudula Avileli1, T V HYNES1
1Oncology Clinical Trials, Horizon Health Network—The Moncton Hospital, Moncton, NB E1C 6Z8, Canada
2Oncology and Hematology Division, Horizon Health Network—The Moncton Hospital, Moncton, NB E1C 6Z8, Canada

Tóm tắt

Despite improvements in the diagnosis and treatment of cancers, the incidence of pituitary metastasis has increased. Prostate cancer metastasis to the pituitary, however, is rare, and these tumors usually grow rapidly. They are also more likely to be located in the posterior pituitary, and the presenting symptoms are often nonspecific, which makes early diagnosis challenging. The management of this condition is usually multidisciplinary, and requires careful assessment and decision making. We present a case of a patient who developed prostate cancer metastasis to the pituitary. In this report, we show that patients with prostate cancer on corticosteroid therapy who develop withdrawal symptoms or other endocrine symptoms should be assessed for pituitary and other brain metastasis. This case report also discusses the impact of switching from prednisone and abiraterone to dexamethasone and abiraterone. Our report shows that patients on abiraterone and prednisone whose PSA has increased, but who have no radiologic progression, may have their PSA controlled and thereby improved survival time when they are switched to abiraterone and dexamethasone.

Từ khóa


Tài liệu tham khảo

Javanbakht, 2018, Pituitary metastasis: A rare condition, Endocr. Connect, 7, 1049, 10.1530/EC-18-0338

Ng, 2020, Current status and treatment modalities in metastases to the pituitary: A systematic review, J. Neurooncol., 146, 219, 10.1007/s11060-020-03396-w

Lozano, 2018, Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study), Br. J. Cancer, 119, 1052, 10.1038/s41416-018-0123-9

Patel, 2003, Rare case of metastatic prostate adenocarcinoma to the pituitary, Urology, 62, 352, 10.1016/S0090-4295(03)00367-4

Zadravec, 2015, Initial symptomatic pituitary metastasis in a patient with prostate foamy gland carcinoma: Tailoring safe and effective therapy, Acta Clin. Croat., 54, 243

Dias, 2018, Pituitary and other sellar region metastases, Curr. Opin. Endocr. Metab. Res., 1, 36, 10.1016/j.coemr.2018.05.001

Yılmaz, H., Kaya, M., Can, M., Ozbek, M., and Keyik, B. (2012). Metastatic prostate adenocarcinoma presenting central diabetes insipidus. Case Rep. Med., 2012.

Komninos, 2004, Tumors metastatic to the pituitary gland: Case report and literature review, J. Clin. Endocrinol. Metab., 89, 574, 10.1210/jc.2003-030395

Lithgow, 2020, Pituitary metastases: Presentation and outcomes from a pituitary center over the last decade, Pituitary, 23, 258, 10.1007/s11102-020-01034-2

Nolan, 2001, Anterior pituitary trophic responses to dexamethasone withdrawal and repeated dexamethasone exposures, J. Endocrinol., 169, 263, 10.1677/joe.0.1690263

Thông tin
Thông tin xuất bản

Current Oncology

Tập 28 Số 6

4291-4297

Thông tin tác giả